Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Breast Cancer, Colo-rectal Cancer, Ovari...
Phase Not Applicable
Enrollment 850
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The PRO-ACTIVE study aims to develop a clinical-translational program in the field of cancer prevention in all its phases (primary, secondary, and tertiary) to intervene before the clinical and radiological manifestation of the disease. It starts with risk prediction and leads to early diagnosis of the disease or recurrence in the subclinical phase. The PRO-ACTIVE study includes the following activities: * WP1: Integrated DNA-RNA approach for the identification of hereditary markers of predisposition to tumors * WP2: Global biological and molecular analysis of the host and tumor for the prevention and monitoring of recurrences * WP3: Analysis of the immunological status for the diagnosis of primary prevention and relapses in correlation to genetic and environmental factors * WP4: Study of the tumor microenvironment for recurrence prediction

Design

Study type: Observational Observational model: Case Only Time perspective: Other

Primary Outcomes

  • Number, frequency and type of genetic variants in known genes not detected by routine diagnostic tests for hereditary tumours (From enrollment to the last clinical follow-up at month 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-02-01
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 850 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione del Piemonte per l'Oncologia
Principal Investigators:
  • Chiara Lazzari, MD (STUDY_CHAIR) - Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo
  • Federico Bussolino, MD (STUDY_CHAIR) - Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo
  • Luigia Pace, PhD (STUDY_CHAIR) - Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo
Contact Information
Study Contact:
Vanesa Gregorc, MD
+390119933915
vanesa.gregorc@ircc.it
Vanesa Gregorc, MD
+390119933915
vanesa.gregorc@ircc.it
Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo
Interventions
N/A
Study Locations (1 sites)
Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo, Candiolo, Turin 10060 Italy
Eligibility Criteria
Inclusion Criteria: * Age \>18 years; * Patients with breast cancer, including patients who meet the AIOM criteria for eligibility for BRCA testing and patients with lobular breast cancer; * Patients with radically resected colon cancer, including patients with stage III colon cancer and vascular invasion; * Patients with ovarian carcinomas; * Patients with metastatic melanoma; * Patients with stage IIB and IIIA non-small cell lung cancer. Exclusion Criteria: * Age \<18 years; * Unwillingness or inability to give informed consent
Conditions HER2-positive Advanced Breast Cancer, Br...
Phase PHASE2
Enrollment 224
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

A total of 224 subjects of HER2-positive advanced breast cancer with brain metastases are planned to be enrolled. Eligible subjects will be randomly assigned in a 1:1 ratio to the group receiving Trastuzumab Rezetecan combined with radiotherapy or the group receiving Trastuzumab Rezetecan monotherapy until disease progression, intolerable toxicity, withdrawal of informed consent, or the study determines that treatment must be terminated (whichever occurs first).

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Trastuzumab Rezetecan — Trastuzumab Rezetecan:4.8mg/kg Q3W
  • Radiation: FSRT or WBRT — FSRT (8Gy/3-5 fx)or WBRT(30Gy/10fx)

Primary Outcomes

  • PFS (up to 1.5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-08-30
Completion: 2032-12-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 224 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Henan Cancer Hospital
Contact Information
Study Contact:
Min Yan professor
+86 15713857388
ym200678@126.com
Professor
Interventions
  • Drug: Trastuzumab Rezetecan — Trastuzumab Rezetecan:4.8mg/kg Q3W
  • Radiation: FSRT or WBRT — FSRT (8Gy/3-5 fx)or WBRT(30Gy/10fx)
Study Locations (1 sites)
Professor, Zhengzhou, Henan China
Eligibility Criteria
Inclusion Criteria: 1. Females ≥18 yrs old; 2. Pathologically confirmed HER2-positive advanced breast cancer; 3. At least one measurable intracranial lesion according to RANO-BM criteria, which had not received local treatment; 4. Without prior cranial radiation and had no indication for immediate local treatment or refuse to local treatment; 5. Life expectancy is not less than 6 months. 6. Adequate function of major organs. Exclusion Criteria: 1. Subjects with leptomeningeal metastasis 2. CNS complications requiring emergency neurosurgical intervention 3. Previous treatment with trastuzumab deruxtecan (DS-8201a) or any other antibody drug conjugate (ADC) which consists of an exatecan derivative that is a topoisomerase 1 inhibitor; 4. Suffering from heart disease that is not well controlled or having clinical symptoms 5. History of clinically significant lung disease; 6. Other malignant tumors, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma, have been diagnosed in the past five years. 7. Female subjects during pregnancy and lactation 8. Any other conditions that researchers believe that patients are unsuitable for this study.
Conditions Axillary Lymph Node Dissection, Patholog...
Phase NA
Enrollment 92
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

This prospective, single-arm, phase II trial studies axillary lymph node dissection (ALND) to see if it can be safely omitted in breast cancer patients with axillary pathological complete response (pCR) after neoadjuvant systemic therapy (NST). Breast cancer patients with biopsy-proven positive axillary lymph nodes at initial diagnosis, and converted to negative after NST, which is confirmed by Stained region Lymph Node Biopsy(SrLNB), will be enrolled in the study. In other words, a total of 92 patients will be exempted from ALND after SrLNB, and afterwards complete regional node irradiation (RNI) including the axilla. They will also undergo adjuvant chemotherapy, targeted therapy, endocrinotherapy after surgery. These patients will be followed up in the next three years for local-regional recurrence and long-time survival outcome.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Stained region Lymph Node Biopsy (SrLNB) — Before NST, carbon nanoparticles suspension would be injected into the cortex of positive lymph nodes for staining under ultrasound guidance. Marked lymph nodes will be removed and biopsied after NST.
  • Radiation: Regional lymph node radiotherapy (RNI) including the axilla — RNI including the axilla covers the supraclavicular region and entire axillary lymphatic drainage area (region I, II and III) ,and is at a dose of 50 Gy/25 times, with additional prophylactic irradiation of the internal breast lymphatic drainage area for eligible patients.

Primary Outcomes

  • iDFS: invasive Disease-Free Survival after breast surgery (Up to 3 years after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-11
Completion: 2026-07
Eligibility
Age: 18 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 92 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University
Contact Information
Study Contact:
Jue Wang, MD
+862568306360
wangjue200011@njmu.edu.cn
Lingjun Ma, MD
+8613186693728
malingjun@stu.njmu.edu.cn
Lingjun Ma
+8613186693728
malingjun@stu.njmu.edu.cn
The First Affiliated Hospital of Nanjing Medical University
Interventions
  • Procedure: Stained region Lymph Node Biopsy (SrLNB) — Before NST, carbon nanoparticles suspension would be injected into the cortex of positive lymph nodes for staining under ultrasound guidance. Marked lymph nodes will be removed and biopsied after NST.
  • Radiation: Regional lymph node radiotherapy (RNI) including the axilla — RNI including the axilla covers the supraclavicular region and entire axillary lymphatic drainage area (region I, II and III) ,and is at a dose of 50 Gy/25 times, with additional prophylactic irradiation of the internal breast lymphatic drainage area for eligible patients.
Study Locations (1 sites)
The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
Eligibility Criteria
Inclusion Criteria: 1. Female aged between 18 and 70 years; 2. Pathologically confirmed invasive breast cancer (regardless of pathological type) with a clinical stage cT1-3; 3. Pathologically confirmed positive axillary lymph nodes with a clinical stage of N1-3; 4. Receiving a full course of neoadjuvant therapy (including neoadjuvant chemotherapy, neoadjuvant targeted therapy, neoadjuvant immunotherapy); 5. Positive axillary lymph nodes successfully stained by carbon nanoparticles injection; 6. All patients are required to undergo immunohistochemical staining for Estrogen Receptor (ER), Progesterone Receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki- 67 proliferation index, and further fluorescence in situ hybridization (FISH) should be performed in HER2 2+ cases; 7. Preoperative clinical assessment (including physical examination, imaging, with or without nomogram assessment) suggests positive axillary lymph nodes converted to negative (ycN0); 8. ECOG score 0 - 1; 9. Patients voluntarily participated in this study and signed the informed consent form Exclusion Criteria: 1. Bilateral breast cancer; 2. Breast cancer during lactation period or pregnancy; 3. Physical examination or imaging examination confirmed presence of distant metastases; 4. Previous history of malignant tumor; 5. History of previous surgery on the affected axilla; or history of surgery affecting the function of the upper extremity; 6. History of radiation therapy to the breast or chest; 7. Positive incision margins for breast-conserving surgery/mastectomy; 8. Positive results of intraoperative rapid freeze pathology (including isolated tumor cells and micrometastases) for SrLNB (ypN+); 9. Those who unable to complete the full course of follow-up adjuvant therapy as prescribed for various reasons; 10. Aspartate transaminase (AST) and alanine transaminase (ALT) ≥ 1.5 times the upper limit of normal, alkaline phosphatase(ALP) ≥ 2.5 times the upper limit of normal, total bile ≥ 1.5 times the upper limit of normal, serum creatinine ≥ 1.5 times the upper limit of normal; Left Ventricular Ejection Fractions (LVEF) \< 50% in cardiac ultrasound; 11. Severe coagulation dysfunction, serious systemic disease, or uncontrolled infection; 12. Without personal freedom and independent civil capacity; 13. Those with mental disorders, addictions, who were not eligible for enrollment in the judgment of the investigator.
Conditions Breast Cancer
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

A study uniquely focused on system-based practice change, measuring the impact of educational interventions on both patients and clinicians for the recognition and management of treatment-related adverse effects for HER2+/HER2 low breast cancer patients on or about to start on HER2 targeted antibody drug conjugates (fam-trastuzumab deruxtecan-nxki or ado-trastuzumab emtansine) and shared decision-making methodologies to improve adverse event (AE) management and patient-clinician communications.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Educational Intervention — The research-specific educational intervention is the enhancement of communications and SDM in AE management. To this end, interventions will include pre-recorded videos that address: 1. SDM methodologies (\~30 minutes) 2. Simulated case role play interactions between a standardized patient actor and clinician participant (\~60 minutes) 3. In depth presentation on AEs associated with HER2-targeted ADC treatments, and the management of these AEs (\~45 minutes) Clinician participant educational intervention videos and patient participant educational intervention videos will be slightly different, as they are each presented from their specific perspectives.

Primary Outcomes

  • Decisional Conflict Scale (DCS) Score (Baseline)
  • Decisional Conflict Scale (DCS) Score (Month 3)
  • Decisional Conflict Scale (DCS) Score (Month 6)
  • Patient HER2-Targeted ADC Related Side Effect Pre-Test Score (Baseline)
  • Patient HER2-Targeted ADC Related Side Effect Post-Test Score (Month 3)
  • Patient HER2-Targeted ADC Related Side Effect Post-Test Score (Month 6)
  • Clinician HER2-Targeted ADC Related Side Effect Pre-Test Score (Baseline)
  • Clinician HER2-Targeted ADC Related Side Effect Post-Test Score (Month 3)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-03
Completion: 2027-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NYU Langone Health
Collaborators: Daiichi Sankyo, Kaplan North America
Principal Investigators:
  • Nancy Chan, MD (PRINCIPAL_INVESTIGATOR) - NYU Langone Health
Contact Information
Study Contact:
Lucia Greco
718-687-8702
Lucia.Greco@nyulangone.org
Nadia Chowdhury
347-327-4988
nadia.chowdhury@nyulangone.org
Lucia Greco
718-687-8702
Lucia.Greco@nyulangone.org
NYU Langone Health
Interventions
  • Behavioral: Educational Intervention — The research-specific educational intervention is the enhancement of communications and SDM in AE management. To this end, interventions will include pre-recorded videos that address: 1. SDM methodologies (\~30 minutes) 2. Simulated case role play interactions between a standardized patient actor and clinician participant (\~60 minutes) 3. In depth presentation on AEs associated with HER2-targeted ADC treatments, and the management of these AEs (\~45 minutes) Clinician participant educational intervention videos and patient participant educational intervention videos will be slightly different, as they are each presented from their specific perspectives.
Study Locations (1 sites)
NYU Langone Health, New York, New York 10016 United States
Eligibility Criteria
Inclusion Criteria, PATIENT participant group: * ≥ 18 years of age * Confirmed diagnosis of HER2+ or HER2 low breast cancer who are receiving or are about to receive HER2-targeted antibody drug conjugates (ADCs) * Patient must be able to sign informed consent and be willing to participate in and comply with protocol requirements (3 visits \[can be virtual\], entry of survey information, access training, subset: 2 interviews and focus group) \[All Virtual\] * Patient must be able to read, speak, and understand English * Access to or ability to 1) enter information on computer or iPad into HIPAA-compliant Intelligent Dashboard online database; and 2) access training on computer or iPad Inclusion Criteria, CLINICIAN participant group: * Clinician agrees to see their own patients at study visits (baseline, interim time point, and end of study) in order to reduce inter-clinician variability that can affect result findings (observe effect of clinician's education on their patients' learning.) * Clinician is a physician, NP, physician assistant, nurse, or pharmacist who works with patients with HER2-positive or HER2-low breast cancer. * Clinician must be willing to participate in and comply with protocol requirements and provide informed consent (per IRB requirements), including availability for interviews (3), case role plays (3), patient visits (3/patient), and training * Clinician agrees to access virtual online training videos: SDM, simulation case role play, management of adverse events for patients receiving HER2-targeted ADCs for HER2-positive or HER2-low breast cancer Exclusion Criteria, PATIENT participant group: * History of noncompliance * Inability to make required "office visits" (in-person or virtual) * Inability to participate in training * Non-ambulatory * Limiting comorbidities (eg. psychiatric diagnosis; significant cognitive impairment limiting ability to fulfill protocol requirements) * Pregnant patients * No internet and computer access Exclusion Criteria, CLINICIAN participant group: • Inability to participate in required virtual visits, training, assessments, and other protocol requirements.
Conditions Breast Cancer
Phase PHASE1
Enrollment 64
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B administered orally as monotherapy OR in combination with Hormonal Therapy in subjects with HR+, HER2- locally advanced and unresectable (Stage III) or metastatic (Stage IV) breast cancer whose disease has progressed during prior therapy with an approved CDK4/6i plus hormonal therapy.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: RGT-419B — oral capsules
  • Drug: RGT-419B in combination with hormonal therapy — RGT-419B in combination with hormonal therapy (Selective Estrogen Receptor Degrader, Selective Estrogen Receptor Modulator, or Aromatase Inhibitor)

Primary Outcomes

  • Safety & Tolerability - Number of subjects with Dose-Limiting Toxicities (DLTs) at each cohort dose level in singlet and doublet therapy (4 weeks (1 cycle))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2022-03-04
Completion: 2027-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 64 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Regor Pharmaceuticals Inc.
Contact Information
Study Contact:
Joanna Dojillo, MSc
617-315-9070
joanna.dojillo@regor.com
Regor Pharmaceuticals Central Office
617-315-9070
rgt-419b_01-101@regor.com
Sauntee Braddock
858-534-8248
sbraddock@health.ucsd.edu
University of California, San Diego
Interventions
  • Drug: RGT-419B — oral capsules
  • Drug: RGT-419B in combination with hormonal therapy — RGT-419B in combination with hormonal therapy (Selective Estrogen Receptor Degrader, Selective Estrogen Receptor Modulator, or Aromatase Inhibitor)
Study Locations (8 sites)
University of California, San Diego, La Jolla, California 92037 United States
University California, Los Angeles, Los Angeles, California 90404 United States
Hem-Onc Associates of the Treasure Coast, Port Saint Lucie, Florida 34952 United States
Moffitt Cancer Center, Tampa, Florida 33612 United States
Emory University, Atlanta, Georgia 30322 United States
Massachusetts General Hospital, Boston, Massachusetts 02142 United States
Washington University School of Medicine, St Louis, Missouri 63110 United States
New York Cancer and Blood Specialists, Port Jefferson Station, New York 11776 United States
Eligibility Criteria
Inclusion Criteria: 1. Male or female \>/= 18 years old 2. ECOG Performance Status 0 to 1 3. Subjects must have histologically or cytologically confirmed diagnosis of ER+, HER2- ABC consistent with ASCO CAP guidelines that is locally advanced and unresectable (Stage III) or metastatic (Stage IV) BC. 4. Measurable AND evaluable lesions at baseline per RECIST v1.1. 5. Eligible subjects must meet all of the following criteria: * Progression after receiving 1 line of prior cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) therapy combined with HT in the MBC setting (up to 1 additional line of CDK4/6i is permitted in the post-surgical adjuvant setting); * Subjects must have received therapy for ≥3 months in the MBC setting, or for ≥6 months in the adjuvant setting, prior to progression * Progression after ≤3 lines of prior HT therapy (regardless of whether it is HT alone or in combination with other therapies) * Prior HT combination agents, including SERD, SERM or AI, must have received formal approval by regulatory agency. * ≤ 1 prior line of chemotherapy in the metastatic setting 6. Adequate organ function 7. Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: 1. Presence of visceral metastases with severe organ dysfunction as evidence by signs and symptoms, laboratory studies, lymphangitic spread and/or rapid progression of disease 2. Pregnant or planning to become pregnant 3. Prior irradiation to \>25% of the bone marrow and/or inadequate bone marrow function or evidence of clinically significant end-organ damage 4. Major surgery, chemotherapy, targeted therapy, experimental agents, or radiation within 14-28 days prior to Cycle 1, Day 1 5. Active, serious medical condition that is not well controlled with locally approved medications allowed by the protocol 6. History of allergic reactions attributed to compounds of similar chemical or biologic composition to the drugs used in the study
Conditions Locally Advanced Triple-negative Breast ...
Phase PHASE2, PHASE3
Enrollment 446
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

Title: A Study to See if BEBT-209 Combined With Chemotherapy Works to Treat People With Triple-Negative Breast Cancer Researchers want to learn if a new drug called BEBT-209 works to treat people with a specific type of breast cancer. This cancer is called locally advanced or metastatic triple-negative breast cancer (TNBC). The study has two parts. In the first part, researchers want to see if the new drug combination can shrink tumors. In the second part, researchers want to see if this treatment helps people live longer. Researchers will put participants into two groups by chance. This is like flipping a coin. Group 1: Participants get BEBT-209 plus two chemotherapy drugs. These drugs are Carboplatin and Gemcitabine. Group 2: Participants get only the two chemotherapy drugs. Researchers will group people based on the treatments they had in the past. Researchers will also check: How long the treatment keeps the cancer from growing. This is called progression-free survival (PFS). If the treatment is safe. Researchers will look for adverse events (AE), such as low blood cell counts. How participants feel. This is called health-related quality of life (HRQoL). How the body uses the drug.

Design

Study type: Interventional Phases: Phase2, Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BEBT-209 capsules — Dosage: 150 mg orally per dose. Schedule: Administered on Day 1 (D1; before dinner), Day 2 (D2; before breakfast), Day 8 (D8; before dinner), and Day 9 (D9; before breakfast) of each 21-day cycle. Timing: On chemotherapy days (D2 and D9), BEBT-209 must be taken at least 30 minutes before breakfast and exactly 4 hours (±0.5 hours) prior to the start of chemotherapy. Duration: Treatment continues until progressive disease (PD), unacceptable toxicity, or withdrawal of consent. Dose adjustment: Dose reductions for BEBT-209 are not permitted.
  • Drug: Carboplatin Injection — Dosage: Intravenous infusion at AUC 2 (Calvert formula: 2 (mg/mL/min) × \[CrCl (mL/min) + 25\]). Schedule: Administered on Day 2 and Day 9 (experimental arm) or Day 1 and Day 8 (control arm) of each 21-day cycle. Precautions: Must be diluted with 5% glucose. Do not use equipment containing aluminum. Dose adjustment: May be reduced to AUC 1.5 (Calvert formula: 1.5 (mg/mL/min) × \[CrCl (mL/min) + 25\]) based on hematological toxicity. If delay exceeds 42 days, treatment must be discontinued.
  • Drug: Gemcitabine Hydrochloride for Injection — Dosage: Intravenous infusion at 1000 mg/m². Schedule: Administered on Day 2 and Day 9 (experimental arm) or Day 1 and Day 8 (control arm) of each 21-day cycle. Preparation: Diluted with 0.9% sodium chloride (with a gemcitabine concentration of ≤40 mg/mL); do not refrigerate after dilution. Dose adjustment: May be reduced to 800 mg/m² based on toxicity. If delay exceeds 42 days, treatment must be discontinued.

Primary Outcomes

  • Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) (Phase IIb) (From randomization until disease progression or end of treatment or death (up to 24 months).)
  • Overall Survival (OS) (Phase III) (From randomization until death (up to 48 months).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Status: Recruiting
Start Date: 2026-06-04
Completion: 2030-12
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 446 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: BeBetter Med Inc
Collaborators: Hunan Cancer Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Principal Investigators:
  • Quchang Ouyang, PhD (PRINCIPAL_INVESTIGATOR) - Hunan Cancer Hospital
  • Qiang Liu, PhD (PRINCIPAL_INVESTIGATOR) - Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Information
Study Contact:
Kegang Jiang, Master
+86-18664786382
kjiang@bebettermed.com
Yueying Liang
+86-13370266729
yueying.liang@bebettermed.com
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Jiajing Tang
+86-19198021737
jiajing.tang@bebettermed.com
Hunan Cancer Hospital
Interventions
  • Drug: BEBT-209 capsules — Dosage: 150 mg orally per dose. Schedule: Administered on Day 1 (D1; before dinner), Day 2 (D2; before breakfast), Day 8 (D8; before dinner), and Day 9 (D9; before breakfast) of each 21-day cycle. Timing: On chemotherapy days (D2 and D9), BEBT-209 must be taken at least 30 minutes before breakfast and exactly 4 hours (±0.5 hours) prior to the start of chemotherapy. Duration: Treatment continues until progressive disease (PD), unacceptable toxicity, or withdrawal of consent. Dose adjustment: Dose reductions for BEBT-209 are not permitted.
  • Drug: Carboplatin Injection — Dosage: Intravenous infusion at AUC 2 (Calvert formula: 2 (mg/mL/min) × \[CrCl (mL/min) + 25\]). Schedule: Administered on Day 2 and Day 9 (experimental arm) or Day 1 and Day 8 (control arm) of each 21-day cycle. Precautions: Must be diluted with 5% glucose. Do not use equipment containing aluminum. Dose adjustment: May be reduced to AUC 1.5 (Calvert formula: 1.5 (mg/mL/min) × \[CrCl (mL/min) + 25\]) based on hematological toxicity. If delay exceeds 42 days, treatment must be discontinued.
  • Drug: Gemcitabine Hydrochloride for Injection — Dosage: Intravenous infusion at 1000 mg/m². Schedule: Administered on Day 2 and Day 9 (experimental arm) or Day 1 and Day 8 (control arm) of each 21-day cycle. Preparation: Diluted with 0.9% sodium chloride (with a gemcitabine concentration of ≤40 mg/mL); do not refrigerate after dilution. Dose adjustment: May be reduced to 800 mg/m² based on toxicity. If delay exceeds 42 days, treatment must be discontinued.
Study Locations (2 sites)
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120 China
Hunan Cancer Hospital, Changsha, Hunan 410013 China
Eligibility Criteria
Inclusion Criteria Participants must meet all of the following criteria to be eligible for the study: 1. Age and gender: Female, aged 18 to 75 years (inclusive). 2. Informed consent: Voluntarily signed the written informed consent form (ICF). 3. Diagnosis: Pathologically confirmed hormone receptor (HR)-negative and human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic triple-negative breast cancer (TNBC). 4. HR-negative: \<1% of nuclei stain positive for estrogen receptor (ER) and progesterone receptor (PR) by immunohistochemistry (IHC). HER2-negative: IHC 0, 1+, or IHC 2+ with negative in situ hybridization (ISH). 5. Prior therapy: Must have received at least one but no more than two prior systemic therapies for unresectable locally advanced or metastatic disease. Progression within 12 months of completion of neoadjuvant/adjuvant therapy is considered one line of systemic therapy. 6. Measurable disease: At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. 7. Performance status: Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, with stable status within 2 weeks prior to screening (clinically insignificant decline). 8. Life expectancy: At least 12 weeks. 9. Organ function: Adequate organ and bone marrow function (no blood transfusion or growth factors within 2 weeks prior to screening): (1)Absolute neutrophil count (ANC) ≥ 1,500/mm³; (2) Platelets ≥ 100,000/mm³; (3) Hemoglobin ≥ 9 g/dL; (4) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × upper limit of normal (ULN) (or ≤ 5.0 × ULN with liver metastases); (5) Total bilirubin ≤ 1.5 × ULN (or ≤ 3 × ULN with liver metastases); (6) Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 60 mL/min (Cockcroft-Gault). 10.Toxicity recovery: Prior anti-cancer therapy toxicities resolved to ≤ grade 1 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 6.0 (excluding alopecia or other stable toxicities deemed safe by the investigator). 11.Contraception: Negative serum pregnancy test within 7 days before treatment for women of childbearing potential. Agree to use highly effective contraception during the study and for 6 months after the last dose. Note: The initial documentation of locally advanced or metastatic disease must be supported by biopsy, pathology, or imaging reports with specific dates. Systemic therapy includes systemic treatments for TNBC, such as chemotherapy, targeted therapy, and immunotherapy. Exclusion Criteria Participants meeting any of the following criteria will be excluded: 1. Prior treatment history: Prior treatment with gemcitabine. 2. Prior treatment with carboplatin for unresectable locally recurrent or metastatic breast cancer (unless completed in the (neo)adjuvant setting \>6 months prior to first metastatic relapse). 3. Central nervous system (CNS) metastases: Known CNS metastases or leptomeningeal disease (including leptomeningeal metastases, spinal cord metastases, spinal cord compression, and unstable brain metastases). Participants with stable brain metastases (clinically/radiographically stable for at least 4 weeks) are eligible. 4. Pulmonary conditions: Clinically significant pulmonary diseases (e.g., pulmonary embolism within 3 months, severe asthma, severe chronic obstructive pulmonary disease (COPD), restrictive lung disease, significant pleural effusion) or autoimmune/inflammatory diseases with lung involvement. Current interstitial lung disease (ILD)/pneumonitis requiring systemic steroids, or active ILD/pneumonitis suggested by baseline imaging. 5. Effusion and cachexia: Uncontrolled moderate to large pleural, pericardial, or abdominal effusion requiring repeated drainage, or cachexia. 6. Transplantation: Prior history of hematopoietic stem cell or bone marrow transplantation. 7. Prohibited concomitant medications (within 7 days prior to first dose): (1) Strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers; (2) Medications known to significantly prolong the QT interval or cause torsades de pointes (e.g., quinidine, disopyramide, procainamide, sotalol). 8.Washout periods for prior anti-tumor therapy: Radiotherapy or oral small-molecule targeted therapy within 14 days; cytotoxic chemotherapy within 21 days; systemic anti-tumor therapies (e.g., macromolecules, immune checkpoint inhibitors, antibody-drug conjugates (ADCs)) within 28 days; cell therapy within 3 months. 9.Hypersensitivity: Known or suspected hypersensitivity to BEBT-209, carboplatin, gemcitabine, or any of their excipients. 10.Cardiac abnormalities: Significant electrocardiogram (ECG) abnormalities: QTcF \> 480 msec (based on the mean of triplicate ECGs if the first is \>480 msec); History of long QT syndrome (personal or family); Clinically significant ventricular arrhythmia or current use of anti-arrhythmic drugs/implantable cardioverter-defibrillator (ICD). 11.Electrolyte imbalance: Uncontrolled electrolyte disturbances (e.g., hypocalcemia \<1.0 mmol/L, hypokalemia \<3.0 mmol/L, hypomagnesemia \<0.5 mmol/L) that increase QTc prolongation risk (re-screening allowed after intervention). 12.Cardiovascular/cerebrovascular disease (within 6 months): 1. New York Heart Association (NYHA) Class III-IV congestive heart failure or uncontrolled heart failure/coronary artery disease; 2. Clinically significant arrhythmias (e.g., symptomatic atrial fibrillation/flutter) or NCI CTCAE v6.0 grade ≥ 3 arrhythmias; 3. Myocardial infarction, severe/unstable angina, stroke, transient ischemic attack (TIA), symptomatic pulmonary embolism, coronary artery bypass grafting (CABG), or percutaneous coronary intervention (PCI); 4. Refractory hypertension: systolic blood pressure (SBP) \> 160 mmHg and/or diastolic blood pressure (DBP) \> 100 mmHg despite ≥ 3 types of antihypertensive medications. 13.Gastrointestinal issues: Active inflammatory bowel disease, chronic diarrhea, short bowel syndrome, gastrectomy, or any malabsorption syndrome that may impair BEBT-209 absorption. 14.Active infections of clinical significance, including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related diseases, and active syphilis infection. Active hepatitis B is defined as positive hepatitis B surface antigen (HBsAg) or hepatitis B e antigen (HBeAg) with HBV DNA above the upper limit of normal (ULN) of the study center. Patients with HBV DNA quantification above the ULN are permitted to receive antiviral therapy prior to screening and may be enrolled once viral load decreases to within the normal range; however, anti-HBV therapy must be continued throughout the study period. Active hepatitis C is defined as HCV RNA above the detection limit. Active syphilis infection is defined as positive treponemal antibody with positive nontreponemal test (rapid plasma reagin \[RPR\] or toluidine red unheated serum test \[TRUST\]). 15.Diabetes: Poorly controlled diabetes (hemoglobin A1c (HbA1c) ≥ 8.5%). 16.Other malignancies: Other progressive malignancies or malignancies treated within the past 5 years (excluding cured basal/squamous cell skin cancer or cervical carcinoma in situ). 17.Psychiatric/neurological conditions: Active suicidal ideation or behavior within 3 months; current neurological disorders ≥ NCI CTCAE v6.0 grade 2. 18.General exclusion: Any other severe medical, psychiatric, or laboratory abnormality that, in the investigator's opinion, increases participant risk or interferes with study results.
Conditions Breast Carcinoma, Esophageal Carcinoma, ...
Phase Not Applicable
Enrollment 5000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

This study collects information on the side effects of proton therapy and detailed information on the proton therapy treatment plan itself. This may help researchers develop methods to predict the risk of side effects for future patients and learn the long-term benefit of proton therapy.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Other: Quality-of-Life Assessment — Complete questionnaires
  • Other: Questionnaire Administration — Complete questionnaires

Primary Outcomes

  • Acute toxicities data in patients treated with proton therapy (Up to 90 days after end of treatment)
  • Late toxicities data in patients treated with proton therapy (Starting 90 days or more after the end of radiotherapy)
  • Dose-response relationships for normal tissue toxicity after proton therapy (Up to 3 months after therapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2005-05-27
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 5000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: M.D. Anderson Cancer Center
Principal Investigators:
  • Steven J Frank (PRINCIPAL_INVESTIGATOR) - M.D. Anderson Cancer Center
Contact Information
Study Contact:
Steven J. Frank
713-563-2300
sjfrank@mdanderson.org
Steven J. Frank
713-563-2300
M D Anderson Cancer Center
Steven J. Frank
M D Anderson Cancer Center
Interventions
  • Other: Quality-of-Life Assessment — Complete questionnaires
  • Other: Questionnaire Administration — Complete questionnaires
Study Locations (1 sites)
M D Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * All patients scheduled for radiation treatment with protons at UTMDACC are eligible for this protocol * Patients must sign a study-specific consent form prior to study entry Exclusion Criteria: * Patients who are unable or unwilling to attend the required periodic follow-ups either at M.D. Anderson or at a different site
Conditions Breast Cancer Screening, Artificial Inte...
Phase NA
Enrollment 8000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

A randomized prospective study comparing the evaluation of mammography images in a breast cancer screening programme by a single radiologist with AI support versus standard double reading by two radiologists without AI support.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Group with AI iCAD version 3 — Reading mammograms by one radiologist with AI support
  • Diagnostic Test: Group without AI — Standard double reading by two radiologists without AI.

Primary Outcomes

  • Further assessment rate (up to 190 days after screening mammmography)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-06
Completion: 2028-10-05
Eligibility
Age: 45 Years – 69 Years
Sex: FEMALE
Volunteers: true
Enrollment: 8000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital Olomouc
Contact Information
Study Contact:
Lucia Veverkova, MD
+420603181913
lucia.veverkova@fnol.cz
Interventions
  • Diagnostic Test: Group with AI iCAD version 3 — Reading mammograms by one radiologist with AI support
  • Diagnostic Test: Group without AI — Standard double reading by two radiologists without AI.
Study Locations (1 sites)
University Hospital Olomouc, Olomouc, Czechia
Eligibility Criteria
Inclusion Criteria: * age 45-69, asymptomatic woman participating in breast cancer screening programme Exclusion Criteria: * clinical signs of breast disease - indication for diagnostic mammography
Conditions Breast Cancer
Phase NA
Enrollment 1600
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to provide information about the genomics of your breast cancer which your oncologist can use to enhance the treatment of your disease possibly enabling more targeted and personalised therapy.This study will carry out TruSight Oncology Comprehensive (TSOComprehensive) testing on breast cancer tumour tissue that was collected at the time of your breast cancer diagnosis or during your breast surgery or if you have brain metastasis and you have had a biopsy for this. The TruSight Oncology Comprehensive assay is a next-generation sequencing (NGS) test used to analyse cancer-related genomic changes in patients, offering a comprehensive view of potential mutations and other alterations that can impact treatment decisions. The TruSight Oncology Comprehensive assay is CE-IVD marked for use in Europe, meaning that it complies with the relevant EU regulation, for comprehensive genomic profiling for different types of cancer. It analyses 523 cancer-relevant genes from both DNA and RNA to identify variations. It will also look for changes and mutations which may affect cell growth and stability. By identifying relevant mutations and biomarkers, the assay can help oncologists select the most appropriate treatment strategies with the aim of improving patient outcomes.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: TSO500 Assay — Utilisation of TSO500 assay to identify somatic, clinically actionable somatic in the primary breast tumour and, where relevant, brain metastatic tumour to the treating physician to inform clinical management of participating patients.

Primary Outcomes

  • Proportion of enrolled patients with at least one clinically actionable mutation identified by PRISM diagnostics compared with standard-of-care diagnostics. (At the time of therapeutic decision following diagnostic assessment (up to 6 weeks from enrollment).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-11
Completion: 2030-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cancer Trials Ireland
Collaborators: Royal College of Surgeons, Ireland
Contact Information
Study Contact:
Cancer Trials Ireland
00353 1 6677211
info@cancertrials.ie
Leonie Young
00 353 1 797 7800
lyoung@rcsi.com
Cancer Clinical Trials Unit
Beaumont RCSI Cancer Centre
Interventions
  • Diagnostic Test: TSO500 Assay — Utilisation of TSO500 assay to identify somatic, clinically actionable somatic in the primary breast tumour and, where relevant, brain metastatic tumour to the treating physician to inform clinical management of participating patients.
Study Locations (3 sites)
Beaumont RCSI Cancer Centre, Dublin, Leinster D09V2N0 Ireland
Cork University Hospital, Cork, Ireland
University Hospital Galway, Galway, Ireland
Eligibility Criteria
Inclusion Criteria: 1. Patients diagnosed with primary breast cancer attending hospital for the resection of their tumour tissue. Or Patients with suspected or confirmed brain metastatic breast cancer (Patient has a history of a biopsy or surgically (i.e. pathologically) confirmed primary breast cancer) attending hospital for the resection/biopsy and/or treatment of their tumour tissue. Or Patients with suspected (but not necessarily biopsy confirmed) newly diagnosed brain metastatic breast cancer attending hospital for the resection/biopsy and/or treatment of their tumour tissue. 2. Patients receiving neoadjuvant treatment are also eligible (if applicable). 3. Patients must be ≥ 18 years of age. 4. Patients must be able to give informed consent. Exclusion Criteria: 1. Patients who do not have a confirmed diagnosis of primary breast cancer. 2. Patients whose participation, in the opinion of the PI, would not be in their best interest, or those whom in the opinion of the PI would be unsuitable for study for reasons of infirmity or poor health.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 1236
Locations 11 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

This is an international multicenter prospective cohort study aimed at collecting data on breast reconstruction techniques with pre-pectoral implants after mastectomy for breast cancer. The aim of the study is to collect data on the surgical, aesthetic and oncological results, as well as on the quality of life of the patients who will undergo breast reconstruction with a pre-pectoral approach.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: pre-pectoral breast reconstruction — to prospectively evaluate the utilization of the pre-pectoral approach, and evaluate oncological and aesthetic outcomes related to each type of surgical technique and the use of postmastectomy radiation therapy

Primary Outcomes

  • Number of patients with Implant-loss at three months postoperatively (three months postoperatively)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-09-12
Completion: 2029-06-10
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 1236 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: European Breast Cancer Research Association of Surgical Trialists
Collaborators: EUBREAST ETS
Principal Investigators:
  • Oreste D Gentilini, Dr (STUDY_CHAIR) - IRCCS San Raffaele
Contact Information
Study Contact:
Oreste D Gentilini, Dr
+390226431
gentilini@eubreast.com
Rosa Di Micco, Dr
+390226431
dimicco.rosa@hsr.it
Eduardo Gonzalez, MD
Univesidad de Buenos Aires
Interventions
  • Procedure: pre-pectoral breast reconstruction — to prospectively evaluate the utilization of the pre-pectoral approach, and evaluate oncological and aesthetic outcomes related to each type of surgical technique and the use of postmastectomy radiation therapy
Study Locations (11 sites)
Univesidad de Buenos Aires, Buenos Aires, Argentina
Mansoura Insurance, Al Mansurah, Egypt
Mansoura Oncology, Al Mansurah, Egypt
National ans Kapodistrian University of Athens, Athens, Greece
Ospedale San Raffaele, Milan, MI 20132 Italy
Fondazione Policlinico Universitario Agostino Gemelli, Roma, RM 00136 Italy
University Hospital of Karol Marcinkowski, Zielona Góra, Poland
Prof. Dr. Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania
Hospital del Mar, Barcelona, Spain
Marmara University School of medicine, Istanbul, Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Female patients older than 18 years old * Signed informed consent form * Patients undergoing mono or bilateral therapeutic mastectomy * Patients undergoing pre-pectoral implant-based breast reconstruction with implant or expander with or without mesh Exclusion Criteria: * Male patients * Patients not suitable for surgical treatment * Patients undergoing subpectoral reconstruction * Patients undergoing breast reconstruction with autologous tissue.
Conditions Estrogen Receptor Negative, HER2 Positiv...
Phase NA
Enrollment 120
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial studies eliminating surgery and/or radiation therapy in treating breast cancer patients. In HER2 positive and triple negative breast cancers, after systemic therapy, when image-guided biopsy shows no residual cancer, patients then receive standard breast radiotherapy with no surgery. In ER positive/HER2 negative breast cancers, after endocrine therapy and ablative radiotherapy, when image-guided biopsy shows no residual cancer, patients then receive standard endocrine therapy with no surgery. For patients who have HER2 positive and triple negative breast cancers and standard surgery, after systemic therapy, breast radiotherapy is being eliminated when the pathology from surgery shows no residual cancer.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Undergo EBRT — Undergo EBRT
  • Other: Laboratory Biomarker Analysis — Correlative studies
  • Other: Quality-of-Life Assessment — Ancillary studies
  • Other: Questionnaire Administration — Ancillary studies
  • Radiation: Partial Breast Irradiation — Undergo partial breast irradiation

Primary Outcomes

  • Ipsilateral breast tumor recurrence-free survival (IBT-RFS) (From confirmation of pathologic complete response (pCR) to the time of ipsilateral breast tumor recurrence or death, whichever occurs first or the time of last contact, assessed for up to 10 years)
  • Overall survival (Up to 10 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2017-01-20
Completion: 2028-01-31
Eligibility
Age: 30 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Henry M Kuerer (PRINCIPAL_INVESTIGATOR) - M.D. Anderson Cancer Center
Contact Information
Study Contact:
Henry Kuerer
713-745-5043
hkuerer@mdanderson.org
Laila Samiian
laila.samiian@bmcjax.com
Baptist MD Anderson Cancer Center
Beth A. Lesnikoski
Baptist MD Anderson Cancer Center
Interventions
  • Radiation: Undergo EBRT — Undergo EBRT
  • Other: Laboratory Biomarker Analysis — Correlative studies
  • Other: Quality-of-Life Assessment — Ancillary studies
  • Other: Questionnaire Administration — Ancillary studies
  • Radiation: Partial Breast Irradiation — Undergo partial breast irradiation
Study Locations (8 sites)
MD Anderson Cancer Center - Banner, Gilbert, Arizona 85234 United States
Baptist MD Anderson Cancer Center, Jacksonville, Florida 32207 United States
Queen's Medical Center, Honolulu, Hawaii 96813 United States
Mayo Clinic, Rochester, Minnesota 55905 United States
Cooper Hospital Univ Med Ctr, MD Anderson at Cooper Voorhees, Voorhees Township, New Jersey 08103 United States
Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina 28203 United States
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania 15232 United States
M D Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * Cohort A1 and A2 • Conditions for patient eligibility: Patients on this portion of the study can receive radiation treatment at any MD Anderson Cancer Center or any outside hospital and may be enrolled prior to, during, or following neoadjuvant systemic therapy provided they meet the following eligibility and ineligibility requirements noted below: 1. Pathologically confirmed unicentric invasive breast cancer defined as radiologic clinical stage T1 or T2 (≤ 5 cm), N0 or N1 (≤ 4 abnormal axillary nodes on initial ultrasound), clinical stage M0. 2. HER2 positive (IHC 3+ and or FISH amplified) or triple receptor negative (TN, ER/PR\&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt; 10% HER2 negative (IHC 1+ or 2+ FISH non-amplified) receiving any standard routine clinical NST regimen. 3. Patient desires breast conserving therapy. 4. Age 40 years or older. This age cutoff is justified because breast cancers in women under the age of 40 are known to have a significantly higher risk of IBTR presumably due to underlying biologic differences \[124, 125\]. 5. Female sex. 6. If the patient has a history of a prior non-breast cancer, all treatment for this cancer must have been completed prior to study registration and the patient must have no evidence of disease for this prior non-breast cancer. 7. Patient must have an initial nodal ultrasound that does not demonstrate more than four suspicious lymph nodes, any suspicious lymph nodes should be biopsied to determine if nodal metastatic disease present. 8. Patient understands that the breast lesion size on final breast imaging must be less than or equal to 2 cm prior to the biopsy procedure being performed on study and if the biopsy shows residual carcinoma the patient will be taken off study. * Cohort B1 and B2 • Conditions for patient eligibility: Patients on this portion of the study will be limited to receive radiation treatment at MD Anderson Cancer Center or other approved locations and must be enrolled prior to any neoadjuvant systemic therapy provided they meet the following eligibility and ineligibility requirements noted below: 1. ER and/or PR positive, HER2 negative 2. Clinical stage T1N0M0, unicentric non-lobular breast cancer, no lymphovascular space invasion, 3. At least 40 years of age. 4. Oncotype ≤ 25 if age ≥ 50 years 5. Oncotype 0-20 and tumor size ≤ 1.5cm if age 40-49 years. 6. Patient agrees to take anti-estrogen therapy and is interested in breast conservation 7. Female sex. 8. If the patient has a history of a prior non-breast cancer, all treatment for this cancer must have been completed prior to study registration and the patient must have no evidence of disease for this prior non-breast cancer. 9. No history of prior radiation to the area of the breast that would require protocol-mandated treatment * Cohort C • Conditions for patient eligibility: Patients on this portion of the study can receive surgical treatment at any MD Anderson Cancer Center or any outside hospital and may be enrolled prior to or following neoadjuvant systemic therapy provided they meet the following eligibility and ineligibility requirements noted below: 1. Pathologically confirmed invasive breast cancer defined as radiologic clinical stage T1 or T2 (≤ 5 cm), N0, clinical stage M0 and HER2 positive (IHC 3+ and or FISH amplified) receiving any standard routine clinical NST regimen containing her-2 directed therapy OR Pathologically confirmed invasive breast cancer defined as radiologic clinical stage T1 (≤ 2 cm), N0, clinical stage M0 and triple negative, receiving any standard routine clinical NST regimen. 2. For cohort C patients participating in the optional pretreatment biopsy, the patient should be able undergo biopsy or surgery of the primary tumor site of suspected or proven invasive breast cancer and should be planned to receive neoadjuvant systemic therapy. 3. Patient desires breast conserving therapy. 4. Age 30 years or older if HER2 positive. Age 50 or older if HER2 negative (triple negative). 5. Female sex. 6. If the patient has a history of a prior non-breast cancer, all treatment for this cancer must have been completed prior to study registration and the patient must have no evidence of disease for this prior non-breast cancer. 7. Patient must have an initial nodal ultrasound that does not demonstrate suspicious lymph nodes; any suspicious lymph nodes should be biopsied to determine if nodal metastatic disease present. 8. Patient must have no evidence of residual invasive tumor or DCIS on pathologic review of the lumpectomy surgical specimen 9. Patient must have no evidence of metastatic disease or isolated tumor cells involving the lymph nodes on pathologic review of the lymph node surgical specimen. If treatment effect in the nodes is noted on the pathology report, the investigators would generally discourage enrollment on this protocol. 10. Unifocal disease or limited multifocal disease that can be excised in a single lumpectomy specimen * Cohort D (MD Anderson Houston patients only) * Conditions for patient eligibility: Patients on this portion of the study meet all eligibility requirements for cohort C, but have not enrolled onto the study to omit radiation. Patients in Cohort D can be identified at the time of diagnosis or prior to lumpectomy. They are not required to participate in one of the treatment arms of the study, but can ultimately choose to move to an omission Cohort at a later time point. 3.5.1 Patients with triple negative or her-2 positive tumor who are amenable to breast conserving treatment and have received or are planned for neoadjuvant systemic therapy prior to surgery are eligible for Cohort D. 3.5.2 Eligible patients in cohort D who have undergone optional ARTIDIS biopsies of the primary breast tumor at the time of diagnosis, prior to starting neoadjuvant therapy, or following completion of systemic therapy, at the time of surgery, may later move to Cohort A or C if they meet all eligibility requirements and ultimately desire surgery or radiation omission Exclusion Criteria: 1. Radiologic evidence for a stage T3 or clinical stage T4 breast cancer in Cohort A1/A2/C; radiologic evidence for a stage T2-T3 or clinical stage T4 breast cancer in Cohort B1/B2. 2. Clinical or pathologic evidence for distant metastases. 3. Prior diagnosis of invasive or ductal carcinoma in situ breast cancer in the ipsilateral breast. 4. Clinical evidence of progression of disease \&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;gt;20% in the breast or new evidence of nodal metastases. 5. Patient is known to be pregnant. 6. Patient is participating in a NST protocol in which surgical excision of the breast and or lymph nodes are required in Cohort A1/A2/B1/B2.
Conditions Breast Cancer Stage I
Phase PHASE2
Enrollment 1008
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

For patients with HER2-positive early-stage breast cancer, NCCN guidelines recommend chemotherapy plus targeted therapy as the standard adjuvant treatment for patients with tumors larger than 1 cm or lymph node-positive. The APT study enrolled patients with stage I HER2-positive breast cancer and has confirmed the efficacy and safety of intravenous chemotherapy combined with targeted therapy, but only 2.2% of the patients enrolled in microinvasion are enrolled, and there is a lack of large sample size data to provide a treatment reference for these patients. In order to further explore the optimal strategy for adjuvant therapy in this type of patient, we designed a new clinical trial to evaluate the efficacy and safety of oral capecitabine plus pyrotinib as adjuvant therapy in previous retrospective studies.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Capecitabine,Pyrotinib — Pyrotinib and Capecitabine for half a year

Primary Outcomes

  • iDFS (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-06-01
Completion: 2028-07-01
Eligibility
Age: 18 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 1008 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Zhimin Shao, MD
+86-021-64175590
zhimingshao@yahoo.com
Zhi-Ming Shao, MD
86-21-641755901105
zhimingshao@yahoo.com
Breast cancer institute of Fudan University Cancer Hospital
Ruoxi Wang, MD
86-21-641755901105
08301010259@fudan.edu.cn
Breast cancer institute of Fudan University Cancer Hospital
Interventions
  • Drug: Capecitabine,Pyrotinib — Pyrotinib and Capecitabine for half a year
Study Locations (1 sites)
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: 1. Women aged 18-70; 2. The pathology of early breast cancer after surgery is T1micN0: histologically confirmed that the longest diameter of invasive cancer does not exceed 1mm or the maximum diameter of multiple invasive lesions is less than 1mm, and the lymph node is negative (N0); 3. The pathological type of immunohistochemistry needs to meet the following conditions: HER-2 (3+) or HER-2 (0-2+) but amplified by FISH detection. 4. Hormone receptor negative (HR-) is defined as ER, PR expression is \<1%; Hormone receptor positivity (HR+) is defined as ER and/or PR expression ≥1%. 5. For patients with both invasive lesions, if both lesions are HER-2 positive, they can be enrolled. 6. ECOG score≦ 1 point; 7. No obvious dysfunction of major organs; 8. Blood routine: ANC ≥1.5×109/L, PLT≥100×109/L, blood Hb≥ 9 g/dl (no transfusion within 14 days); 9. Liver function: total bilirubin ≤1.25×ULN; AST and ALT \<2.5×ULN; 10. Renal function: creatinine clearance ≥ 50 mL/min, blood creatinine ≤ 1.5 ×ULN; 11. Cardiac function: ECG is generally normal, QTc\< 470 ms; LVEF \> 50%; 12. contraception during treatment for women of childbearing age; 13. No history of other malignant tumors in the past 5 years; 14. With the consent of the person and signed the informed consent form, or signed by the patient's legal representative with the authorization of the patient. 15. Can be followed up and good compliance. Exclusion Criteria: 1. The maximum size of the infiltrate is more than 1mm in diameter or the axillary lymph node is positive 2. HER2 negative: immunohistochemical HER2-,+; Immunohistochemical HER2+ while FISH has no amplification; 3. Patients who have received neoadjuvant therapy or any other form of systemic therapy or local therapy other than surgery, including chemotherapy, targeted, radiotherapy, or endocrine therapy, prior to enrollment 4. History of other malignant tumors, except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix; 5. Metastasis of any part; 6. Pregnant or lactating women, women of childbearing age who cannot be effectively contraceptives; 7. Patients who participate in other clinical trials at the same time; 8. Severe organ function (heart, lung, liver and kidney) insufficiency, LEVF \< 50% (ultracardiogram); severe cardiovascular and cerebrovascular diseases (such as: unstable angina, chronic heart failure, uncontrollable hypertension \>150/90mmgh, myocardial infarction or cerebrovascular accident) within 6 months before enrollment; diabetics with poor glycemic control; Patients with severe hypertension; 9. Severe or uncontrolled infection; 10. Those who have a history of psychotropic substance abuse and cannot quit or have a history of mental disorders; 11. Patients who are judged by the investigator to be unsuitable to participate in this study.